BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:21 PM
 | 
Jun 11, 2007
 |  BC Extra  |  Clinical News

Ipsen discontinuing four-month formulation of Decapeptyl

Ipsen (Euronext:IPN) will discontinue an open-label, single-arm Phase III trial of a four-month sustained-release formulation of Decapeptyl in 100 prostate cancer patients. The...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >